Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Supercomputer Simulates Beating Heart, Helping Drive Research

By LabMedica International staff writers
Posted on 04 Dec 2012
A new supercomputer had been built specifically to tackle weapon simulations, but before it goes into its intended work, it is generating cutting-edge cardiac simulations.

The Sequoia [IBM’s BlueGene/Q] holds the number two rank in the November 2012 TOP500 list of the world’s fastest computer systems [top ranked in the June 2012 TOP500 list]. More...


Sequoia is bringing modeling and simulation and modeling to new peaks, timing in at 16.32 sustained petaflops (20 PF peak), enabling scientists to capture greater complexity in a shorter period. With this advanced capability, Lawrence Livermore US National Laboratory’s (LLNL; Livermore, CA, USA) scientists have been able to simulate the human heart down to the cellular level and use the resulting model to predict how the organ will respond to different drug compounds.

The simulations were made possible by an advanced modeling program, called Cardioid, which was designed by a group of scientists from LLNL and the IBM T. J. Watson Research Center (Yorktown Heights, NY, USA). The extremely scalable code simulates the electrophysiology of the heart. It functions by breaking down the heart into units: the smaller the unit, the more effective the model. Up to now, the optimal modeling programs could attain 0.2 mm in each direction. Cardioid can jump down to 0.1 mm. Where earlier, researchers could run the simulations for tens of heartbeats, Cardioid executing on Sequoia captures thousands of heartbeats.

Scientists are experiencing 300-fold speedups. It used to take 45 minutes to simulate just one beat, but now researchers can simulate an hour of heart activity--several thousand heartbeats--in seven hours. With the less sophisticated codes, it was impossible to model the heart’s response to a drug or perform an electrocardiogram trace for a particular heart disorder. That sort of testing entails longer run times, which was not possible before Cardioid.

The model could hypothetically evaluate a range of medications and devices such as pacemakers to examine their effect on the heart, creating an avenue for more effective and safer human testing. But it is particularly suited to examining arrhythmia, a disorder of the heart in which the organ does not pump blood efficiently. Arrhythmias can lead to congestive heart failure, an inability of the heart to supply sufficient blood flow to meet the needs of the body.

There are various types of medications that disrupt cardiac rhythms. Even those designed to prevent arrhythmias can be detrimental to some patients, and researchers do not yet completely understand precisely what causes these negative side effects. Cardioid will enable LLNL scientists to examine heart function as an antiarrhythmia drug enters the bloodstream. They will be able to identify when drug levels are highest and when they decline. “Observing the full range of effects produced by a particular drug takes many hours,” noted computational scientist Art Mirin of LLNL. “With Cardioid, heart simulations over this timeframe are now possible for the first time.”

The Livermore-IBM group is also working on a mechanical model that simulates the contraction of the heart and pumping of blood. The mechanical and electrical simulations will be allowed to interact with each other, adding more realism to the heart model.

The cardiac modeling research was performed during the system’s “shakedown period”--the set-up and assessment stage--and the scientists had to rush to complete in the allotted time span. Once Sequoia becomes classified, it is uncertain if it will still be available to run Cardioid and other unclassified programs, although access will certainly be more difficult since the computer’s key mission is running nuclear weapons codes.

Sequoia is an integral part of the US National Nuclear Security Administration’s (NNSA) Advanced Simulation and Computing (ASC) program, which is run by partner organizations LLNL, Los Alamos US National Laboratory, and Sandia National Laboratories. With 96 racks, 98,304 compute nodes, 1.6 million cores, and 1.6 petabytes of memory, Sequoia will help the NNSA fulfill its mission to “maintain and enhance the safety, security, reliability, and performance of the US nuclear weapons stockpile without nuclear testing.”

The Cardioid simulation has been chosen as a finalist in the 2012 Gordon Bell Prize competition, awarded each year to recognize supercomputing’s ultimate achievements. The scientists divulged their findings at the Supercomputing Conference in Salt Lake City (UT, USA), on November 13, 2012.

Related Links:

Lawrence Livermore U.S. National Laboratory
IBM T. J. Watson Research Center
US National Nuclear Security Administration




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.